Annovis Bio press release (NYSE:ANVS): Q3 GAAP EPS of -$0.97 misses by $0.58.
As of November 8, 2024, Annovis had cash and cash equivalents of $13.6 million. The company has an adequate runway for all Phase 3 preparatory studies and for entering the pivotal